UK prospective diabetes study (UKPDS) View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1991-12

AUTHORS

UK Prospective Diabetes Study Group

ABSTRACT

The UK Prospective Diabetes Study (UKPDS) is a multi-centre, prospective, randomised, intervention trial of 5100 newly-diagnosed patients with Type 2 (non-insulin-dependent) diabetes mellitus which aims to determine whether improved blood glucose control will prevent complications and reduce the associated morbidity and mortality. Newly presenting Type 2 diabetic patients aged 25–65 years inclusive, median age 53 years, median body mass index 28 kg/m2 and median fasting plasma glucose 11.3 mmol/l, were recruited and treated initially by diet. Ninety five percent remained hyperglycaemic (fasting plasma glucose > 6 mmol/l) and were randomly allocated to different therapies. In the main randomisation, those who were asymptomatic and had fasting plasma glucose under 15 mmol/l were allocated either to diet policy, or to active policy with either insulin or sulphonylurea aiming to reduce the fasting plasma glucose to under 6 mmol/l. Over 3 years, the median fasting plasma glucose in those allocated to diet policy was 8.9 mmol/l compared with 7.0 mmol/l in those allocated to active policy. The Hypertension in Diabetes Study has been included in a factorial design to assess whether improved blood pressure control will be advantageous. Patients with blood pressure ≥ 160/90 mm Hg were randomly allocated to tight control aiming for < 150/85 mm Hg with either an angiotensin-converting enzyme inhibitor or a Beta-blocker or to less tight control aiming for < 200/105 mm Hg. The endpoints of the studies are major clinical events which affect the life and well-being of patients, such as heart attacks, angina, strokes, amputations, blindness and renal failure. To date, 728 patients have had at least one clinical endpoint. Surrogate endpoints include indices of macrovascular and microvascular disease detected by ECG with Minnesota Coding, retinal colour photography and microalbuminuria. The studies also aim to evaluate potential risk factors for the development of diabetic complications such as smoking, obesity, central adiposity, plasma LDL-and HDL-cholesterol, triglyceride, insulin, urate and other biochemical variables. The studies are planned to terminate in 1994, with a median follow-up of 9 years (range 3–16 years) for the glucose study and 5 years (range 2–6 years) for the hypertension study. More... »

PAGES

877-890

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00400195

DOI

http://dx.doi.org/10.1007/bf00400195

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1022043816

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1778353


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diet, Diabetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Research Design", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United Kingdom", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Royal Devon and Exeter Hospital, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.416118.b", 
          "name": [
            "Radcliffe Infirmary, Oxford", 
            "Royal Infirmary, Aberdeen", 
            "General Hospital, Birmingham", 
            "St George's Hospital and Hammersmith Hospital, London", 
            "City Hospital, Belfast", 
            "North Staffordshire Royal Infirmary, Stoke-on-Trent", 
            "Royal Victoria Hospital, Belfast", 
            "St. Helier Hospital, Carshalton", 
            "Whittington Hospital, London", 
            "Norfolk and Norwich Hospital, UK", 
            "Lister Hospital, Stevenage", 
            "Ipswich Hospital, UK", 
            "Ninewells Hospital, Dundee", 
            "Northampton Hospital, UK", 
            "Torbay Hospital, Peterborough General Hospital, UK", 
            "Scarborough Hospital, UK", 
            "Derbyshire Royal Infirmary, UK", 
            "Manchester Royal Infirmary, UK", 
            "Hope Hospital, Salford", 
            "Leicester General Hospital, UK", 
            "Royal Devon and Exeter Hospital, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "UK Prospective Diabetes Study Group", 
        "id": "sg:person.014003710051.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014003710051.15"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00265546", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038663411", 
          "https://doi.org/10.1007/bf00265546"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00401052", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044105011", 
          "https://doi.org/10.1007/bf00401052"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00257424", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034044950", 
          "https://doi.org/10.1007/bf00257424"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00257337", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011564100", 
          "https://doi.org/10.1007/bf00257337"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03216217", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025033216", 
          "https://doi.org/10.1007/bf03216217"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00282581", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032703668", 
          "https://doi.org/10.1007/bf00282581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00405009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048739310", 
          "https://doi.org/10.1007/bf00405009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00274216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037368755", 
          "https://doi.org/10.1007/bf00274216"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00297455", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008725966", 
          "https://doi.org/10.1007/bf00297455"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1991-12", 
    "datePublishedReg": "1991-12-01", 
    "description": "The UK Prospective Diabetes Study (UKPDS) is a multi-centre, prospective, randomised, intervention trial of 5100 newly-diagnosed patients with Type 2 (non-insulin-dependent) diabetes mellitus which aims to determine whether improved blood glucose control will prevent complications and reduce the associated morbidity and mortality. Newly presenting Type 2 diabetic patients aged 25\u201365 years inclusive, median age 53 years, median body mass index 28 kg/m2 and median fasting plasma glucose 11.3 mmol/l, were recruited and treated initially by diet. Ninety five percent remained hyperglycaemic (fasting plasma glucose > 6 mmol/l) and were randomly allocated to different therapies. In the main randomisation, those who were asymptomatic and had fasting plasma glucose under 15 mmol/l were allocated either to diet policy, or to active policy with either insulin or sulphonylurea aiming to reduce the fasting plasma glucose to under 6 mmol/l. Over 3 years, the median fasting plasma glucose in those allocated to diet policy was 8.9 mmol/l compared with 7.0 mmol/l in those allocated to active policy. The Hypertension in Diabetes Study has been included in a factorial design to assess whether improved blood pressure control will be advantageous. Patients with blood pressure \u2265 160/90 mm Hg were randomly allocated to tight control aiming for < 150/85 mm Hg with either an angiotensin-converting enzyme inhibitor or a Beta-blocker or to less tight control aiming for < 200/105 mm Hg. The endpoints of the studies are major clinical events which affect the life and well-being of patients, such as heart attacks, angina, strokes, amputations, blindness and renal failure. To date, 728 patients have had at least one clinical endpoint. Surrogate endpoints include indices of macrovascular and microvascular disease detected by ECG with Minnesota Coding, retinal colour photography and microalbuminuria. The studies also aim to evaluate potential risk factors for the development of diabetic complications such as smoking, obesity, central adiposity, plasma LDL-and HDL-cholesterol, triglyceride, insulin, urate and other biochemical variables. The studies are planned to terminate in 1994, with a median follow-up of 9 years (range 3\u201316 years) for the glucose study and 5 years (range 2\u20136 years) for the hypertension study.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf00400195", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1001482", 
        "issn": [
          "0012-186X", 
          "1432-0428"
        ], 
        "name": "Diabetologia", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "12", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "34"
      }
    ], 
    "keywords": [
      "UK Prospective Diabetes Study", 
      "Prospective Diabetes Study", 
      "plasma glucose", 
      "Diabetes Study", 
      "angiotensin-converting enzyme inhibitor", 
      "improved blood glucose control", 
      "median age 53 years", 
      "type 2 diabetic patients", 
      "median body mass index", 
      "improved blood pressure control", 
      "type 2 diabetes mellitus", 
      "retinal colour photography", 
      "blood pressure control", 
      "age 53 years", 
      "major clinical events", 
      "HDL-cholesterol", 
      "body mass index", 
      "blood glucose control", 
      "potential risk factors", 
      "being of patients", 
      "associated morbidity", 
      "blood pressure", 
      "renal failure", 
      "microvascular disease", 
      "Glucose Study", 
      "diabetes mellitus", 
      "diabetic patients", 
      "mass index", 
      "central adiposity", 
      "glucose control", 
      "clinical events", 
      "Hypertension Study", 
      "intervention trials", 
      "clinical endpoints", 
      "risk factors", 
      "diabetic complications", 
      "Minnesota coding", 
      "different therapies", 
      "surrogate endpoints", 
      "plasma LDL", 
      "enzyme inhibitors", 
      "patients", 
      "pressure control", 
      "biochemical variables", 
      "heart attack", 
      "endpoints", 
      "complications", 
      "insulin", 
      "glucose", 
      "Hg", 
      "tight control", 
      "years", 
      "angina", 
      "color photography", 
      "microalbuminuria", 
      "hypertension", 
      "mellitus", 
      "morbidity", 
      "sulphonylureas", 
      "smoking", 
      "obesity", 
      "adiposity", 
      "study", 
      "control", 
      "randomisation", 
      "amputation", 
      "therapy", 
      "LDL", 
      "stroke", 
      "triglycerides", 
      "mortality", 
      "disease", 
      "trials", 
      "index", 
      "blindness", 
      "ECG", 
      "diet", 
      "inhibitors", 
      "percent", 
      "failure", 
      "factors", 
      "life", 
      "m2", 
      "events", 
      "date", 
      "pressure", 
      "factorial design", 
      "active policy", 
      "development", 
      "variables", 
      "being", 
      "attacks", 
      "photography", 
      "policy", 
      "design", 
      "coding", 
      "main randomisation"
    ], 
    "name": "UK prospective diabetes study (UKPDS)", 
    "pagination": "877-890", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1022043816"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00400195"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1778353"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00400195", 
      "https://app.dimensions.ai/details/publication/pub.1022043816"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_258.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf00400195"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00400195'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00400195'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00400195'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00400195'


 

This table displays all metadata directly associated to this object as RDF triples.

262 TRIPLES      22 PREDICATES      145 URIs      127 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00400195 schema:about N1359f7012cbc4e7c986a49b6d0092e32
2 N1687d57aa6c74cdc81cb56006c89298f
3 N17d42cf9cbcc428f8f2974cf87658913
4 N2cd352a77b8c4cd8b59c41aa7e93033d
5 N34c80c9291ca40ab9d3f3e0573d77740
6 N3a5e9ff1fba0463d930c504db5fb3215
7 Ncc96ace0ae654bd397d1a55ca438ed6e
8 Ncf51c4dc441d4ec2be3c6c4f6ec71ea4
9 Nd0207f6449804c08ab03b609499aa83a
10 Nd2e0aee9b07c4288bb4fa995057f0114
11 Nd5eb00fbb62745e7bdfbada09cff2acf
12 anzsrc-for:11
13 anzsrc-for:1102
14 anzsrc-for:1103
15 schema:author N4d4ce1aee2ff40888267b7d7c002e5a0
16 schema:citation sg:pub.10.1007/bf00257337
17 sg:pub.10.1007/bf00257424
18 sg:pub.10.1007/bf00265546
19 sg:pub.10.1007/bf00274216
20 sg:pub.10.1007/bf00282581
21 sg:pub.10.1007/bf00297455
22 sg:pub.10.1007/bf00401052
23 sg:pub.10.1007/bf00405009
24 sg:pub.10.1007/bf03216217
25 schema:datePublished 1991-12
26 schema:datePublishedReg 1991-12-01
27 schema:description The UK Prospective Diabetes Study (UKPDS) is a multi-centre, prospective, randomised, intervention trial of 5100 newly-diagnosed patients with Type 2 (non-insulin-dependent) diabetes mellitus which aims to determine whether improved blood glucose control will prevent complications and reduce the associated morbidity and mortality. Newly presenting Type 2 diabetic patients aged 25–65 years inclusive, median age 53 years, median body mass index 28 kg/m2 and median fasting plasma glucose 11.3 mmol/l, were recruited and treated initially by diet. Ninety five percent remained hyperglycaemic (fasting plasma glucose > 6 mmol/l) and were randomly allocated to different therapies. In the main randomisation, those who were asymptomatic and had fasting plasma glucose under 15 mmol/l were allocated either to diet policy, or to active policy with either insulin or sulphonylurea aiming to reduce the fasting plasma glucose to under 6 mmol/l. Over 3 years, the median fasting plasma glucose in those allocated to diet policy was 8.9 mmol/l compared with 7.0 mmol/l in those allocated to active policy. The Hypertension in Diabetes Study has been included in a factorial design to assess whether improved blood pressure control will be advantageous. Patients with blood pressure ≥ 160/90 mm Hg were randomly allocated to tight control aiming for < 150/85 mm Hg with either an angiotensin-converting enzyme inhibitor or a Beta-blocker or to less tight control aiming for < 200/105 mm Hg. The endpoints of the studies are major clinical events which affect the life and well-being of patients, such as heart attacks, angina, strokes, amputations, blindness and renal failure. To date, 728 patients have had at least one clinical endpoint. Surrogate endpoints include indices of macrovascular and microvascular disease detected by ECG with Minnesota Coding, retinal colour photography and microalbuminuria. The studies also aim to evaluate potential risk factors for the development of diabetic complications such as smoking, obesity, central adiposity, plasma LDL-and HDL-cholesterol, triglyceride, insulin, urate and other biochemical variables. The studies are planned to terminate in 1994, with a median follow-up of 9 years (range 3–16 years) for the glucose study and 5 years (range 2–6 years) for the hypertension study.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree true
31 schema:isPartOf N2f11e2240ec0470e8b97fd58ecb0f836
32 N354df1b6656348e4be0bb2f219d21888
33 sg:journal.1001482
34 schema:keywords Diabetes Study
35 ECG
36 Glucose Study
37 HDL-cholesterol
38 Hg
39 Hypertension Study
40 LDL
41 Minnesota coding
42 Prospective Diabetes Study
43 UK Prospective Diabetes Study
44 active policy
45 adiposity
46 age 53 years
47 amputation
48 angina
49 angiotensin-converting enzyme inhibitor
50 associated morbidity
51 attacks
52 being
53 being of patients
54 biochemical variables
55 blindness
56 blood glucose control
57 blood pressure
58 blood pressure control
59 body mass index
60 central adiposity
61 clinical endpoints
62 clinical events
63 coding
64 color photography
65 complications
66 control
67 date
68 design
69 development
70 diabetes mellitus
71 diabetic complications
72 diabetic patients
73 diet
74 different therapies
75 disease
76 endpoints
77 enzyme inhibitors
78 events
79 factorial design
80 factors
81 failure
82 glucose
83 glucose control
84 heart attack
85 hypertension
86 improved blood glucose control
87 improved blood pressure control
88 index
89 inhibitors
90 insulin
91 intervention trials
92 life
93 m2
94 main randomisation
95 major clinical events
96 mass index
97 median age 53 years
98 median body mass index
99 mellitus
100 microalbuminuria
101 microvascular disease
102 morbidity
103 mortality
104 obesity
105 patients
106 percent
107 photography
108 plasma LDL
109 plasma glucose
110 policy
111 potential risk factors
112 pressure
113 pressure control
114 randomisation
115 renal failure
116 retinal colour photography
117 risk factors
118 smoking
119 stroke
120 study
121 sulphonylureas
122 surrogate endpoints
123 therapy
124 tight control
125 trials
126 triglycerides
127 type 2 diabetes mellitus
128 type 2 diabetic patients
129 variables
130 years
131 schema:name UK prospective diabetes study (UKPDS)
132 schema:pagination 877-890
133 schema:productId N4067e50ba8aa4766b94e567db2e7c4f7
134 N8577cb417c9140e4848fc1b2d37ffaee
135 N9799825dad234f91a26b990370db93c4
136 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022043816
137 https://doi.org/10.1007/bf00400195
138 schema:sdDatePublished 2021-11-01T18:00
139 schema:sdLicense https://scigraph.springernature.com/explorer/license/
140 schema:sdPublisher Nae3bacf9a9ac4d1daa1bffac0155f90e
141 schema:url https://doi.org/10.1007/bf00400195
142 sgo:license sg:explorer/license/
143 sgo:sdDataset articles
144 rdf:type schema:ScholarlyArticle
145 N1359f7012cbc4e7c986a49b6d0092e32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Diet, Diabetic
147 rdf:type schema:DefinedTerm
148 N1687d57aa6c74cdc81cb56006c89298f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Middle Aged
150 rdf:type schema:DefinedTerm
151 N17d42cf9cbcc428f8f2974cf87658913 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name United Kingdom
153 rdf:type schema:DefinedTerm
154 N2cd352a77b8c4cd8b59c41aa7e93033d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Adult
156 rdf:type schema:DefinedTerm
157 N2f11e2240ec0470e8b97fd58ecb0f836 schema:issueNumber 12
158 rdf:type schema:PublicationIssue
159 N34c80c9291ca40ab9d3f3e0573d77740 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Antihypertensive Agents
161 rdf:type schema:DefinedTerm
162 N354df1b6656348e4be0bb2f219d21888 schema:volumeNumber 34
163 rdf:type schema:PublicationVolume
164 N3a5e9ff1fba0463d930c504db5fb3215 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Research Design
166 rdf:type schema:DefinedTerm
167 N4067e50ba8aa4766b94e567db2e7c4f7 schema:name dimensions_id
168 schema:value pub.1022043816
169 rdf:type schema:PropertyValue
170 N4d4ce1aee2ff40888267b7d7c002e5a0 rdf:first sg:person.014003710051.15
171 rdf:rest rdf:nil
172 N8577cb417c9140e4848fc1b2d37ffaee schema:name pubmed_id
173 schema:value 1778353
174 rdf:type schema:PropertyValue
175 N9799825dad234f91a26b990370db93c4 schema:name doi
176 schema:value 10.1007/bf00400195
177 rdf:type schema:PropertyValue
178 Nae3bacf9a9ac4d1daa1bffac0155f90e schema:name Springer Nature - SN SciGraph project
179 rdf:type schema:Organization
180 Ncc96ace0ae654bd397d1a55ca438ed6e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Blood Glucose
182 rdf:type schema:DefinedTerm
183 Ncf51c4dc441d4ec2be3c6c4f6ec71ea4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Diabetes Mellitus, Type 2
185 rdf:type schema:DefinedTerm
186 Nd0207f6449804c08ab03b609499aa83a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Humans
188 rdf:type schema:DefinedTerm
189 Nd2e0aee9b07c4288bb4fa995057f0114 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Hypertension
191 rdf:type schema:DefinedTerm
192 Nd5eb00fbb62745e7bdfbada09cff2acf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Prospective Studies
194 rdf:type schema:DefinedTerm
195 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
196 schema:name Medical and Health Sciences
197 rdf:type schema:DefinedTerm
198 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
199 schema:name Cardiorespiratory Medicine and Haematology
200 rdf:type schema:DefinedTerm
201 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
202 schema:name Clinical Sciences
203 rdf:type schema:DefinedTerm
204 sg:journal.1001482 schema:issn 0012-186X
205 1432-0428
206 schema:name Diabetologia
207 schema:publisher Springer Nature
208 rdf:type schema:Periodical
209 sg:person.014003710051.15 schema:affiliation grid-institutes:grid.416118.b
210 schema:familyName UK Prospective Diabetes Study Group
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014003710051.15
212 rdf:type schema:Person
213 sg:pub.10.1007/bf00257337 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011564100
214 https://doi.org/10.1007/bf00257337
215 rdf:type schema:CreativeWork
216 sg:pub.10.1007/bf00257424 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034044950
217 https://doi.org/10.1007/bf00257424
218 rdf:type schema:CreativeWork
219 sg:pub.10.1007/bf00265546 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038663411
220 https://doi.org/10.1007/bf00265546
221 rdf:type schema:CreativeWork
222 sg:pub.10.1007/bf00274216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037368755
223 https://doi.org/10.1007/bf00274216
224 rdf:type schema:CreativeWork
225 sg:pub.10.1007/bf00282581 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032703668
226 https://doi.org/10.1007/bf00282581
227 rdf:type schema:CreativeWork
228 sg:pub.10.1007/bf00297455 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008725966
229 https://doi.org/10.1007/bf00297455
230 rdf:type schema:CreativeWork
231 sg:pub.10.1007/bf00401052 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044105011
232 https://doi.org/10.1007/bf00401052
233 rdf:type schema:CreativeWork
234 sg:pub.10.1007/bf00405009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048739310
235 https://doi.org/10.1007/bf00405009
236 rdf:type schema:CreativeWork
237 sg:pub.10.1007/bf03216217 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025033216
238 https://doi.org/10.1007/bf03216217
239 rdf:type schema:CreativeWork
240 grid-institutes:grid.416118.b schema:alternateName Royal Devon and Exeter Hospital, Exeter, UK
241 schema:name City Hospital, Belfast
242 Derbyshire Royal Infirmary, UK
243 General Hospital, Birmingham
244 Hope Hospital, Salford
245 Ipswich Hospital, UK
246 Leicester General Hospital, UK
247 Lister Hospital, Stevenage
248 Manchester Royal Infirmary, UK
249 Ninewells Hospital, Dundee
250 Norfolk and Norwich Hospital, UK
251 North Staffordshire Royal Infirmary, Stoke-on-Trent
252 Northampton Hospital, UK
253 Radcliffe Infirmary, Oxford
254 Royal Devon and Exeter Hospital, Exeter, UK
255 Royal Infirmary, Aberdeen
256 Royal Victoria Hospital, Belfast
257 Scarborough Hospital, UK
258 St George's Hospital and Hammersmith Hospital, London
259 St. Helier Hospital, Carshalton
260 Torbay Hospital, Peterborough General Hospital, UK
261 Whittington Hospital, London
262 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...